The global Artificial Organs and Bionics Market is expected to witness substantial growth, projected to reach US$ 50.7 ...

A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway;1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah ...

(RTTNews) - Trestle Biotherapeutics, Inc. has partnered with Humacyte, Inc. (HUMA) to explore synergies in bioengineering vascularized organs for transplantation. Trestle Bio, a preclinical-stage ...

This study was the world’s first FDA-cleared clinical trial using a bioengineered liver. Based on these positive results, United Therapeutics (UTHR) will initiate a phase 2 study Approximately 30% of ...

United Therapeutics’ bioengineered external liver assist system developed to treat patients with acute forms of chronic liver failure proved promising based on early phase 1 trial results. Five ...

Intermountain Medical Center participated in a trial of the first bioengineered external liver, designed to help acute liver failure patients or are not eligible for or are waiting for a transplant a ...

In a breakthrough that brings bioengineered organs one step closer to reality, scientists have created lab-grown liver tissue capable of forming its own blood vessels. A team from Cincinnati ...

BROOKLYN, N.Y., April 2, 2025 /PRNewswire/ -- Xylyx Bio, Inc., a regenerative medicine company, announced that it has received $1,000,000 from the Richard M. Bartlett Jr. Memorial Foundation and ...

SAN DIEGO--(BUSINESS WIRE)--Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing ...